In the last few decades, DNA analysis has transformed the field of microbiology. Culture techniques – previously the standard – leave up to 50% of bacterial species virtually invisible. The GI-MAP??utilizes cutting-edge FDA-approved technology to provide a true DNA-based assessment of a patient’s gut microbiome from a single stool sample. This arms the clinician with actionable information on microbes that are well-researched to cause disease or disrupt normal microbial balance and contribute to many inflammatory, autoimmune, metabolic, cardiovascular, and other chronic diseases.

What Makes?The GI-MAP? Different?
  • Automated, multiplex PCR analysis method, allowing for the simultaneous measurement of multiple bacteria, fungi, parasites, and viruses
  • Single stool sample
  • DNA sequencing of 16S and 23S rRNA allows for superior sensitivity and specificity in?the detection of 15 of the most common causes of gastroenteritis, as well as other chronic diseases
  • Intestinal health markers allow for a?comprehensive analysis of your gut microbiome, together with markers of inflammation, mucosal immune system and digestion
  • Quantitative and qualitative analysis?providing superior clarity to results
  • Evidence-based and transparent
  • The GI-MAP opens the door to find infections otherwise missed. Culturing techniques are limited in what organisms they can grow and they cannot accurately quantify numbers.?Similarly, sequencing?analyses only one region of the genome. There are many examples of microbes that cannot be measured easily, or at all, by sequencing. For example, most pathogens, especially all of the E. coli strains and C. difficile.
  • Additionally, this test addresses virulence factors for pathogens which can further elucidate treatment – To treat or not to treat, that is the question.
  • Validated by 3rd parties. If results are positive, the same stool sample can be run in another lab that does PCR and find the same result.
  • qPCR measures both the 16S and 23S regions ribosomal RNA. The gene sequence 16S has been proven to be a reliable genetic marker as it is present (conserved) in all bacteria and its function has not changed over time. Additionally, measuring the 23S region enables further detection capabilities with variable regions.
  • Automation minimises human error.
  • This technique allows the analysis of further targets without increasing price and labour.

This is why it is the methodology of choice for microbiome researchers and now – via Diagnostic Laboratory – to Functional and Integrative Medicine practitioners for better patient outcomes.